Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide + SGLT2i in T2DM (AWARD-10)
NCT02597049Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2015
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
A Phase 3 trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Nov 2015; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02597049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597049.